NARI Stock Likely to Gain Following Reimbursement Approval in Japan [Yahoo! Finance]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Yahoo! Finance
NARI also entered into a distribution deal with Medikit Co. Ltd, a global medical device company, to facilitate the commercialization of the Clotriever system in Japan. Following the announcement, shares of the company closed flat at $52.12 on Monday. However, in the year-to-date period, NARI's shares have lost 19.7% against the industry's 6.4% growth. The S&P 500 increased 27.1% in the same time frame. The reimbursement approval and the new distribution deal with Medikit are likely to help NARI boost its ClotTriever sales in Japan and its overall revenues, which will likely increase the stock's price. Meanwhile, the company currently has a market capitalization of $3.04 billion. NARI delivered an average earnings surprise of 24.8% in the last four quarters. Image Source: Zacks Investment Research NARI's ClotTriever system is anFDA 510(k)-cleared and CE-Marked mechanical thrombectomy device specifically designed for the treatment of DVT. The 500-patient ClotTriever CLOUT Regi
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor EventBusiness Wire
- ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife [Yahoo! Finance]Yahoo! Finance
- AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- NanoKnife gains FDA clearance for prostate tissue ablation [Yahoo! Finance]Yahoo! Finance
ANGO
Earnings
- 10/3/24 - Miss
ANGO
Sec Filings
- 12/4/24 - Form 4
- 12/4/24 - Form 3
- 11/15/24 - Form 8-K
- ANGO's page on the SEC website